Investing.com - Cellectis reported on Thursday third quarter earnings that missed analysts' forecasts and revenue that fell short of expectations.
Cellectis announced earnings per share of $-0.71 on revenue of $9.24M. Analysts polled by Investing.com anticipated EPS of $-0.58 on revenue of $10.36M.
Cellectis shares are up 5.9% from the beginning of the year and are trading at $18.13 , down-from-52-week-high.They are under-performing the Nasdaq which is up 32.52% from the start of the year.
Cellectis follows other major Healthcare sector earnings this month
Cellectis's report follows an earnings beat by J&J on October 13, who reported EPS of $2.2 on revenue of $21.08B, compared to forecasts EPS of $1.98 on revenue of $20.2B.
Thermo Fisher Scientific had beat expectations on October 21 with third quarter EPS of $5.63 on revenue of $8.52B, compared to forecast for EPS of $4.33 on revenue of $7.65B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar